167 related articles for article (PubMed ID: 1665123)
1. In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria.
Louie A; Baltch AL; Ritz WJ; Smith RP
Chemotherapy; 1991; 37(4):275-82. PubMed ID: 1665123
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
Rotstein C; Amsterdam D; Beam TR; Mandell LA; Gorzynski EA
Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
[TBL] [Abstract][Full Text] [Related]
3. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
Wallrauch C; Voss A; Milatovic D; Braveny I
Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
[TBL] [Abstract][Full Text] [Related]
4. Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents.
Louie A; Baltch AL; Ritz WJ; Smith RP
J Antimicrob Chemother; 1991 Jun; 27(6):793-9. PubMed ID: 1657857
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of four new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.
Ling TK; Liu EY; Cheng AF
Chemotherapy; 1999; 45(1):22-7. PubMed ID: 9876206
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
Dalhoff A; Petersen U; Endermann R
Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria.
Cohen MA; Huband MD; Mailloux GB; Yoder SL; Roland GE; Heifetz CL
Diagn Microbiol Infect Dis; 1991; 14(5):403-15. PubMed ID: 1665775
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of HSR-903, a new quinolone.
Takahashi Y; Masuda N; Otsuki M; Miki M; Nishino T
Antimicrob Agents Chemother; 1997 Jun; 41(6):1326-30. PubMed ID: 9174193
[TBL] [Abstract][Full Text] [Related]
13. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
[TBL] [Abstract][Full Text] [Related]
14. Bactericidal kinetics and postantibiotic effect of sparfloxacin against selected species of respiratory pathogens.
Speciale A; Blandino G; Nicolosi VM; Siracusa V; Caccamo F
J Chemother; 1995 Dec; 7(6):530-4. PubMed ID: 8667038
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci.
Rudrik JT; Ferrigno SR; Gee SL
Diagn Microbiol Infect Dis; 1991; 14(4):355-60. PubMed ID: 1889186
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of DV-7751a, a new fluoroquinolone.
Tanaka M; Hoshino K; Ishida H; Sato K; Hayakawa I; Osada Y
Antimicrob Agents Chemother; 1993 Oct; 37(10):2112-8. PubMed ID: 8257132
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
Gootz TD; Brighty KE; Anderson MR; Schmieder BJ; Haskell SL; Sutcliffe JA; Castaldi MJ; McGuirk PR
Diagn Microbiol Infect Dis; 1994 Aug; 19(4):235-43. PubMed ID: 7851087
[TBL] [Abstract][Full Text] [Related]
19. [In vitro comparative activity (E test) of sparfloxacin and other 8 antimicrobial agents against bacteria isolated from patients with respiratory infections acquired in the community].
Prado V; Trucco O; Nina A; Salamanca L; Juliet C; Braun S
Rev Med Chil; 1995 Nov; 123(11):1394-1401. PubMed ID: 8733283
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of BAY Y3118, a new full-spectrum fluoroquinolone.
Bremm KD; Petersen U; Metzger KG; Endermann R
Chemotherapy; 1992; 38(6):376-87. PubMed ID: 1288961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
